Clinical Trials Directory

Trials / Conditions / Refractory Metastatic Colorectal Cancer

Refractory Metastatic Colorectal Cancer

12 registered clinical trials studyying Refractory Metastatic Colorectal Cancer — 5 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingTrifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic
NCT07261709
Sun Yat-sen UniversityPhase 2
RecruitingA Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
NCT07361003
Jiangsu Simcere Pharmaceutical Co., Ltd.Phase 3
RecruitingEvaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followe
NCT06607458
Delcath Systems Inc.Phase 2
Not Yet RecruitingNimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer
NCT06343116
Biotech Pharmaceutical Co., Ltd.Phase 3
RecruitingAmplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevaciz
NCT05991102
Charite University, Berlin, GermanyN/A
TerminatedRP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
NCT05733611
Replimune, Inc.Phase 2
UnknownNKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
NCT05213195
Zhejiang UniversityPhase 1
Active Not RecruitingVorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Me
NCT05205330
Rottapharm BiotechPhase 1 / Phase 2
UnknownNKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer
NCT05248048
The Third Affiliated Hospital of Guangzhou Medical UniversityEARLY_Phase 1
CompletedPhase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Can
NCT04737187
Taiho Oncology, Inc.Phase 3
UnknownQL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer
NCT04527068
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 2
CompletedA Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
NCT02860546
Taiho Oncology, Inc.Phase 2